Randomized Trial of Dual Antibody Induction Therapy With Steroid Avoidance in Renal Transplantation

Abstract

These two distinct dual-induction therapies with rTd, EC-MPS, and planned early corticosteroid withdrawal resulted in favorable rates of BPAR and all secondary outcomes.

Graft Failure Due to Noncompliance Among 628 Kidney Transplant Recipients With Long-term Follow-up

“…Our prospectively followed cohort of 628 adult, primary kidney-alone transplant recipients consists of all participants in four randomized immunosuppression trials performed at our center since May 2000 (27, 46Y49 (100 patients per arm), with maintenance in both arms consisting of tacrolimus, enteric-coated mycophenolate sodium (using one-half of standard dose in the ATG/ alemtuzumab arm), and planned early corticosteroid withdrawal (49); last follow-up date was May 2010. The center institutional review board approved each protocol; all patients gave written informed consent before enrollment (Clinical Trials.gov ID: NCT00681213, NCT00685061, NCT00681343, NCT00533624, and NCT01172418).…”

Single-centre study of 628 adult, primary kidney transplant recipients showing no unfavourable effect of new-onset diabetes after transplant

“…We were therefore interested in determining the prognostic impact of NODAT among patients receiving transplants at our centre. To maximise statistical power, we combined data for all study participants in four randomised immunosuppression trials of adult, primary kidney transplantation performed at our centre since May 2000 [22][23][24][25][26][27][28][29][30][31][32], yielding a prospectively followed cohort of 628 patients. Results from this observational study are presented here.…”

“…: NCT00681213, NCT00685061, NCT00681343, NCT00533624 and NCT01172418; note: two distinct registration numbers exist in the second trial, because separate randomisations of deceased donor and living donor recipients were performed). Results of these randomised trials have been reported previously (details omitted here) [22][23][24][25][26][27][28][29][30][31][32].…”

Antibody-Mediated Rejection in Cardiac Transplantation: Emerging Knowledge in Diagnosis and Management

“…Most are case reports describing alemtuzumab as salvage or induction therapy. 123,163,[166][167][168][169][170][171][172][173][174][175][176] In a small group of lung transplant recipients with rejection refractory to steroids and ATG, alemtuzumab appeared to be effective in reversing rejection and bronchiolitis obliterans syndrome. 177 Treatment of rejection appears similarly effective in kidney transplant recipients but may be associated with increased early infection-related deaths.…”